Key Performance
More- Earnings Score: N/A
- Momentum Score: 31
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Disc Medicine, Inc. (NASDAQ: IRON) received a Complete Response Letter from the FDA on February 13, 2026, rejecting its bitopertin drug application due to uncertainties requiring additional evidence. The stock fell 22% following the announcement. Rosen Law Firm is investigating potential securities fraud claims and preparing a class action lawsuit on behalf of affected shareholders.
09/04/2026, 5:26 PM • GlobeNewswire
Disc Medicine to Participate in Upcoming Investor Conferences
Disc Medicine (NASDAQ: IRON), a clinical-stage biopharmaceutical company focused on hematologic diseases, announced participation in four major investor conferences in September 2026. The company also reported completing a Type A FDA meeting on bitopertin with Phase 3 APOLLO study data expected in Q4 2026, which could serve as the basis for a Complete Response Letter (CRL) response.
09/02/2026, 8:00 AM • GlobeNewswire
Disc Medicine announced it will present clinical data from multiple programs at the SOHO 2026 Annual Meeting in Houston, including initial Phase 2 RESTORE-PV trial data for DISC-3405 in polycythemia vera patients and efficacy data from the RALLY-MF trial of DISC-0974 for myelofibrosis-associated anemia. The oral presentations are scheduled for September 9-12, 2026.
08/31/2026, 6:00 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. Disc Medicine's stock price fell 22% on the news. Investors who purchased Disc Medicine securities may be eligible to join a class action lawsuit seeking recovery of losses.
08/29/2026, 4:23 PM • GlobeNewswire
Rosen Law Firm, a securities litigation firm, is investigating potential fiduciary duty breaches and securities claims against BellRing Brands, Intuit, and Disc Medicine. Current shareholders are encouraged to contact the firm to learn about their legal rights regarding potential losses.
08/29/2026, 4:22 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. Disc Medicine's stock price fell 22% on the news. Investors who suffered losses are encouraged to join a prospective class action.
08/25/2026, 8:40 PM • GlobeNewswire
Rosen Law Firm is notifying investors in Verra Mobility Corporation, Microsoft Corporation, and Disc Medicine, Inc. of upcoming deadlines to join securities class action lawsuits. The firm is seeking lead plaintiffs for cases involving alleged materially false statements and concealed material facts, with the primary deadline for Verra Mobility set for August 4, 2026.
07/22/2026, 10:51 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. The stock price fell 22% on the news, and the firm is preparing a class action lawsuit to recover investor losses.
07/22/2026, 8:28 PM • GlobeNewswire
Rosen Law Firm is investigating potential securities claims against Putnam Investment Management LLC, Sportradar Group AG, and Disc Medicine Inc., alleging materially misleading business information was issued to investors. Affected investors are encouraged to join class action lawsuits seeking compensation for losses.
07/15/2026, 5:50 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter on February 13, 2026, rejecting the company's bitopertin drug application due to uncertainties requiring additional evidence. The rejection caused Disc Medicine's stock to fall 22%. Investors who suffered losses are encouraged to join a prospective class action lawsuit.
07/15/2026, 3:04 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine shareholders after the FDA issued a Complete Response Letter on February 13, 2026, regarding the company's bitopertin program, citing uncertainties requiring additional evidence. The stock fell 22% following the announcement. Investors who suffered losses are encouraged to join a prospective class action.
07/11/2026, 3:01 PM • GlobeNewswire
Disc Medicine, Inc. (NASDAQ: IRON) received a Complete Response Letter from the FDA on February 13, 2026, rejecting its bitopertin drug application due to uncertainties requiring additional evidence. The rejection caused the stock to plummet 22%. The Rosen Law Firm is now pursuing a class action lawsuit on behalf of shareholders who suffered losses, alleging the company issued materially misleading business information.
07/05/2026, 9:58 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following an FDA Complete Response Letter on February 13, 2026, regarding its bitopertin program. The FDA stated it could not approve the new drug application due to uncertainties requiring additional evidence. The stock price fell 22% on the news, and investors who suffered losses are encouraged to join a prospective class action lawsuit.
07/01/2026, 9:27 PM • GlobeNewswire
Rosen Law Firm has filed class action lawsuits against Embecta Corp. for allegedly making false statements about fiscal results and pen needle business performance, cutting 2026 guidance. The firm is also investigating claims against Zoetis Inc. and Disc Medicine Inc. Investors who purchased securities during specified periods may be eligible for compensation.
06/28/2026, 8:38 PM • GlobeNewswire
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) for allegedly issuing materially misleading business information. The investigation was triggered by an FDA Complete Response Letter on February 13, 2026, regarding the company's bitopertin program, which caused the stock to fall 22%. Investors who suffered losses are encouraged to join a prospective class action lawsuit.
06/28/2026, 5:41 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 09/11/2026
Company Profile
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.